USA flag logo/image

An Official Website of the United States Government

SBIR Phase I: Early Growth Metabolic Responses of Mycobacteria

Award Information

Agency:
National Science Foundation 		Branch:
N/A 		Award ID:
79473 		Program Year/Program:
2006 / SBIR
Agency Tracking Number:
0610806 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
BioSense Technologies Inc.
4 ARROW DR WOBURN, MA 01801-2040
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2006
Title: SBIR Phase I: Early Growth Metabolic Responses of Mycobacteria
Agency: NSF
Contract: 0610806
Award Amount: $100,000.00
 

Abstract:

This Small Business Innovation Research Phase I project describes a method for the drug susceptibility testing of mycobacteria having speed and simplicity. The technical approach is based on a novel implementation of impedance sensing to monitor cellular growth with exceptional sensitivity and stability. Impedance sensing of microbiological growth has not received the attention of optical methods and is ripe for significant technical advances. The responses corresponding to the effects from different antimicrobial compounds are recorded and used to determine the drug susceptibility of viable slow-growing organisms as well as identify multi-drug resistant mycobacteria. The high sensitivity of the approach enables diagnostic results to be obtained without the need for grown cultures reducing the time from sample collection to complete diagnosis by many weeks compared to currently used methods. The organism M. tuberculosis is responsible for 9 million people becoming ill and 2 million people dying each year worldwide, making it one of the world's leading infectious causes of death. Furthermore, the onset of multi-drug resistant strains of M. tb leaves the United States and all other countries unprepared to mount an adequate defense in the event of an epidemic or intentional widespread exposure. The availability of a practical and affordable method of rapidly determining the drug susceptibility of TB infected specimens would have tremendous impact globally on controlling the spread of tuberculosis and the management of effective policies.

Principal Investigator:

Ronald J. Rieder
Dr
7819333635
rieder@biosensetech.com

Business Contact:

Ronald J. Rieder
Dr
7819333635
rieder@biosensetech.com
Small Business Information at Submission:

BSTI
4 Arrow Drive Woburn, MA 01801

EIN/Tax ID:
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No